Therapeutic Product Portfolio
Nine baskets. One discipline.
Each category represents sourcing depth, regulatory navigation, and market understanding built over years. Select any basket to explore.
Polysaccharide Chemistry Pvt Ltd · Mumbai · All APIs GMP-certified
The Polysacc Philosophy
Why niche is not a limitation —
it is the strategy.
The pharmaceutical industry runs on scale. Volume, margins, generics, tenders. That model works — but it leaves an entire tier of therapeutics underserved: molecules that are scientifically validated, clinically meaningful, but commercially difficult to build.
Polysacc was built to occupy that space deliberately. We call it Niche therapeutics — not because we only work with polysaccharides, but because the mindset that drives our PPS work drives everything we do: find the molecule with real clinical value, understand it better than anyone, and build the supply and narrative around it.
01
Science before scale
We enter categories where the clinical evidence is established but the commercial narrative has not been built. Our job is to connect validated science to underserved markets — not to manufacture demand for unproven molecules.
02
Complexity as a moat
Polysaccharides, iron nano-complexes, active coenzyme vitamins, synthetic glucocorticoids — these are molecules that require deep chemistry, not just formulation expertise. Complexity filters out the generics-only mindset.
03
Therapeutic depth, not breadth
A portfolio of 200 commoditised molecules tells no story. We build depth in fewer areas — understanding the patient journey, the prescriber's dilemma, and the regulatory landscape — so our partners can build real franchises.
04
API to outcome
We don't stop at the bulk drug. Our thinking runs from the chemistry of the API through its formulation, its clinical indication, and its real-world patient impact. That end-to-end perspective is what makes us a niche house, not a trading desk.
"The mass market is well served. The niche is where patients are still waiting."
Est.
Mumbai